Q3 sales growth of 8.9% y-o-y (2.2% organic) Small positive revisions, ‘22/’23e sales up 1.
Redeye comments on Invisio’s announcement of an order for its Intercom system worth SEK13m which is ...
Hanza fortsätter leverera stark tillväxt i kombination med god lönsamhet.
Redeye comments on Sleep Cycle's Q2 report, which was more or less in line with our estimates.
BankNordik is set to distribute ~65% of its market cap to shareholders by 2024 in order to reach its...
Q2 beat on sales and adj. EBIT FY’22 guidance kept intact We leave ’22-‘24e adj.
Bra rapport Trots de många utmaningar som bolaget haft att stångas med under det andra kvartalet så ...
Slår samtliga estimat Försäljningen i Q2 uppgick till 32,2 mkr vilket motsvarar en tillväxt om 46% y...
Försäljningen var stark och omsättningen ökade på samtliga marknader men vi noterar en pressad margi...
The Q2 results were largely in line with the profit warning announced on 9 June, which stated “reven...
Sales +3% vs ABGSCe, +9% vs FactSet cons. Adj. EBIT +9% vs ABGSCe, +17% vs FactSet cons.
Redeye updates its estimates following Carasent’s Q2’22 report, which was a tad weaker than anticipa...
Redeye provides its comments on the Q2 2022 report.
Redeye retains its positive stance towards Vertiseit following a Q2 report fueled with M&A growth.
Q2 report due August 18 We expect sales of SEK 13m and EBIT of -36m Share is trading at ’22e-’24e E...
Q2 sales growth of 1% y-o-y EBIT down 8-6% for ’22e-‘24e Business with Russia on pause for now Q2: S...
We have lowered our 2022e group sales by 9%, following a weaker-than-expected quarter for PET foam, ...
Minskad omsättning i Q4 men bruttomarginalen stärks Omsättningen i Q4 uppgick till EUR 69 m (83) mot...
Redeye provides its initial thoughts on the Q2 2022 report.
We see Eltel’s earnings are to decline this year as H1 cost challenges will continue to burden H2 re...
